I4V-MC-JAJK: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Diabetes Mellitus
Type 1
Спонсор: Eli Lilly & Co.
Налично на:
БГ
Обобщение
Trial status: Authorised
Change from Baseline in C-peptide Area Under the Curve (AUC) [Time Frame: Baseline, Week 52]
Кой може да участва
Age group: 18-64 years, 0-17 years
Gender: Female, Male
Target enrollment: 183 participants
БГ
EN